MHC I and MHC II Antigen Processing Machinery {#s1}
=============================================

MHC I and MHC II Molecules
--------------------------

Under basal physiological conditions both human and murine lymphatic endothelial cells (LEC) express both MHC class I and MHC class II molecules ([@B1]). However, as previously reported for blood endothelial cells (BEC) ([@B2]) the level of MHC II expression differs according to the anatomical location from which the cells are isolated ([@B1], [@B3]). LEC from LN (LN-LEC) express a high number of MHC II molecules while LEC from diaphragm express a much lower number ([@B1]). The MHC II surface expression in LN-LEC is similar to what observed in BEC but less than fibroblastic reticular cells from LN ([@B1]). LEC MHC II molecules are both endogenously synthesized or acquired from hematopoietic cells, as determined by chimera experiments in MHC II^−/−^ mice ([@B1], [@B4], [@B5]). At the transcription level, MHC II expression is regulated by CIITA, which is not a DNA binding factor but instead a transactivator that regulates quantitative aspects of MHC-II expression by binding the MHC-II enhanceosome ([@B6]). CIITA expression is under the control of 4 different promoters (I, II, III, IV) and, in non-professional APC, MHC II expression is mostly regulated by CIITA IV ([@B6]). This promoter is responsive to IFNγ and other pro-inflammatory cytokines, which induce MHC II expression/up-regulation in fibroblasts and BEC ([@B6]). Similarly, in LEC it has been shown that endogenous MHC II expression is controlled by CIITA IV ([@B4], [@B5]). However, it is interesting to notice that, in contrast to other non-professional APC where pro-inflammatory stimuli greatly up-regulate surface MHC II molecules, pro-inflammatory stimuli induce less robust MHC II up-regulation in LEC ([@B3], [@B5], [@B7]). In the future, it would be of interest to analyze why, even though LEC express the type IV INFγ-inducible CIITA, they do not strongly up-regulate MHCII during pro-inflammatory conditions ([@B5]).

The Proteasome and TAP
----------------------

Every cell expresses the constitutive 26S proteasome ([@B8]). This large barrel-shaped protein complex is formed in part by the catalytic 20S core, which consists of two pairs of outer α rings organized in seven α (α1--α7) subunits and two pairs of inner β rings organized in seven β subunits (β1--β7). The outer α subunits function as docking domains that regulate access of substrates to the catalytic chamber. Three of the β subunits (β1, β2, and β5) have proteolytic activities, including caspase-like activity (β1), trypsin-like activity (β2), and chymotrypsin-like activity (β5) ([@B9]). In the 26S proteasome, this 20S core is capped at both ends by the 19S regulatory complex ([@B9]). Ubiquitinated proteins are recognized by the 19S regulatory elements, which transfer them to the 20S for proteolysis ([@B10]). Peptides will then be transported in the ER by the transporter associated with antigen processing (TAP) and trimmed by the ER aminopeptidase I (ERAPI). In the ER the MHC class I heavy chain and β~2~m will transiently associates with TAP to load the peptides into the binding groove ([@B11]).

Following IFNγ or TNFα stimulation, new proteasome subunits are incorporated to generate the immunoproteasome ([@B4], [@B12]). β1 is exchanged with the large multifunctional peptidase 2 (LMP2) (also known as iβ1 or psmb9). β2 is exchanged with the multicatalytic endopeptidase complex-like-1 (MECL-1) (also known as iβ2 or psmb10). β5 is exchanged with the large multifunctional peptidase 7 (LMP7) (also known as iβ5 or psmb8). The 19S regulatory complex is exchanged with the Proteasome Activator α (PA28α) and PA28β, known as 11S regulator ([@B2]). The proteolytic functions of the immunoproteasome are greatly enhanced compared to those of the constitutive proteasome, as the immunoproteasome is more efficient in degrading ubiquitinated proteins and viral proteins, and in generating peptides for MHC-I presentation ([@B13]).

Until a few years ago, the presence of the proteasome in LEC was only indirectly analyzed by determining that TAP deficient mice were much less efficient in presenting MHC-I restricted OVA-derived peptides ([@B7]). However, a recent paper reported proteasome transcripts in LEC and BEC from different anatomical locations \[[Table 1](#T1){ref-type="table"} and ([@B14])\]. All of these endothelial populations expressed comparable transcript levels for constitutive proteasome subunits and 19S regulatory subunits. However, LEC and BEC from LN expressed 5-8-fold higher levels of transcripts for psmb8, psmb9, and psmb10, and twice as much PA28α and β. This suggests that LN-localized LEC preferentially express immunoproteasomes. Similarly, LN-localized LEC and BEC express 2--6 fold higher levels of TAP1 and TAP2, and twice as much ERAP1 and tapasin. Although these cells were isolated from resting LN, this suggests that their MHC-I processing and presentation capability is elevated.

###### 

Comparative transcriptome profiling of antigen processing and presentation pathway genes from mouse lymphatic and blood endothelial cells.

  **Gene**                                    **Description**                                               **Lymph node LEC**                       **Lymph node blood EC**   **Diaphragm LEC**
  ------------------------------------------- ------------------------------------------------------------- ---------------------------------------- ------------------------- -------------------
  **MHC-I AND RELATED**                                                                                                                                                        
  B2m                                         Beta-2 microglobulin                                          477796[^a^](#TN1){ref-type="table-fn"}   450780                    69620
  H2-K1                                       Histocompatibility 2, K1, K region                            221754                                   201711                    28827
  H2-D1                                       Histocompatibility 2, D region locus 1                        107074                                   86751                     24764
  H2-T23                                      Histocompatibility 2, T region locus 23                       10686                                    9464                      6609
  H2-M3                                       Histocompatibility 2, M region locus 3                        2375                                     1656                      1029
  H2-K2                                       Histocompatibility 2, K region locus 2                        1770                                     1203                      904
  Mr1                                         Major histocompatibility complex, class I-related             1430                                     722                       1134
  H2-Ke6                                      H2-K region expressed gene 6                                  1373                                     1642                      1671
  H2-T10                                      Histocompatibility 2, T region locus 10                       949                                      635                       166
  H2-T24                                      Histocompatibility 2, T region locus 24                       771                                      591                       244
  Cd1d1                                       CD1d1 antigen                                                 639                                      386                       197
  H2-Q4                                       Histocompatibility 2, Q region locus 4                        443                                      447                       62
  H2-Q6                                       Histocompatibility 2, Q region locus 6                        436                                      347                       3
  H2-Ke2                                      H2-K region expressed gene 2                                  258                                      321                       258
  H2-Q8                                       NA                                                            194                                      206                       4
  H2-T3                                       Histocompatibility 2, T region locus 3                        21                                       2                         11
  Cd1d2                                       CD1d2 antigen                                                 20                                       25                        3
  H2-M2                                       Histocompatibility 2, M region locus 2                        19                                       194                       4
  H2-M5                                       Histocompatibility 2, M region locus 5                        7                                        14                        6
  H2-Q1                                       histocompatibility 2, Q region locus 1                        3                                        3                         1
  H2-Q10                                      Histocompatibility 2, Q region locus 10                       2                                        11                        6
  H2-Bl                                       Histocompatibility 2, blastocyst                              1                                        2                         1
  **MHC-II AND RELATED**                                                                                                                                                       
  Cd74                                        CD74 antigen (invariant chain)                                1999                                     2517                      64
  H2-Ab1                                      Histocompatibility 2, class II antigen A, beta 1              1063                                     2305                      187
  H2-Aa                                       Histocompatibility 2, class II antigen A, alpha               380                                      1584                      100
  H2-Eb1                                      Histocompatibility 2, class II antigen E beta                 304                                      762                       79
  H2-DMb1                                     Histocompatibility 2, class II, locus Mb1                     103                                      85                        5
  Ciita                                       Class II transactivator                                       36                                       92                        13
  H2-Ob                                       Histocompatibility 2, O region beta locus                     33                                       494                       8
  H2-DMa                                      Histocompatibility 2, class II, locus DMa                     33                                       83                        10
  H2-Oa                                       Histocompatibility 2, O region alpha locus                    11                                       36                        0
  H2-DMb2                                     Histocompatibility 2, class II, locus Mb2                     9                                        51                        1
  H2-Eb2                                      Histocompatibility 2, class II antigen E beta2                2                                        26                        0
  **PROTEASOME**                                                                                                                                                               
  Psma1                                       Proteasome subunit, alpha 1                                   1804                                     1990                      2194
  Psma2                                       Proteasome subunit, alpha 2                                   2436                                     2472                      2091
  Psma3                                       Proteasome subunit, alpha 3                                   1313                                     1320                      1313
  Psma4                                       Proteasome subunit, alpha 4                                   2137                                     1939                      1765
  Psma5                                       Proteasome subunit, alpha 5                                   690                                      680                       635
  Psma6                                       Proteasome subunit, alpha 6                                   4479                                     4501                      4096
  Psma7                                       Proteasome subunit, alpha 7                                   3964                                     3890                      3738
  Psma8                                       Proteasome subunit, alpha 8                                   11                                       52                        16
  Psmb1                                       Proteasome subunit, beta 1                                    3600                                     3617                      3368
  Psmb2                                       Proteasome subunit, beta 2                                    3303                                     2471                      2984
  Psmb3                                       Proteasome subunit, beta 3                                    1751                                     2020                      2107
  Psmb4                                       Proteasome subunit, beta 4                                    2504                                     2775                      2663
  Psmb5                                       Proteasome subunit, beta 5                                    1405                                     1376                      1159
  Psmb6                                       Proteasome subunit, beta 6                                    2893                                     2753                      2380
  Psmb7                                       Proteasome subunit, beta 7                                    4851                                     5900                      2203
  Psmb8                                       Proteasome subunit, beta 8 (LMP7)                             4679                                     4348                      564
  Psmb9                                       Proteasome subunit, beta 9 (LMP2)                             4288                                     4159                      563
  Psmb10                                      Proteasome subunit, beta 10                                   5571                                     6015                      1179
  Psmb11                                      Proteasome subunit, beta 11                                   1                                        6                         3
  Psmc1                                       Proteasome 26S subunit, ATPase 1                              1714                                     1902                      1824
  Psmc2                                       Proteasome 26S subunit, ATPase 2                              2290                                     2252                      2852
  Psmc3                                       Proteasome 26S subunit, ATPase 3                              2431                                     2573                      2450
  Psmc3ip                                     Proteasome 26S subunit, ATPase 3, interacting protein         41                                       30                        58
  Psmc4                                       Proteasome 26S subunit, ATPase, 4                             2271                                     2575                      2753
  Psmc5                                       Protease 26S subunit, ATPase 5                                1763                                     1666                      1815
  Psmc6                                       Proteasome 26S subunit, ATPase, 6                             2164                                     2496                      2319
  Psmd1                                       Proteasome 26S subunit, non-ATPase, 1                         2038                                     2012                      2786
  Psmd10                                      Proteasome 26S subunit, non-ATPase, 10                        982                                      698                       499
  Psmd11                                      Proteasome 26S subunit, non-ATPase, 11                        482                                      502                       450
  Psmd12                                      Proteasome 26S subunit, non-ATPase, 12                        2264                                     2639                      2378
  Psmd13                                      Proteasome 26S subunit, non-ATPase, 13                        267                                      272                       258
  Psmd14                                      Proteasome 26S subunit, non-ATPase, 14                        1289                                     1302                      1376
  Psmd2                                       Proteasome 26S subunit, non-ATPase, 2                         2695                                     2767                      3100
  Psmd3                                       Proteasome 26S subunit, non-ATPase, 3                         1064                                     1201                      1117
  Psmd4                                       Proteasome 26S subunit, non-ATPase, 4                         1057                                     1213                      1307
  Psmd5                                       Proteasome 26S subunit, non-ATPase, 5                         726                                      827                       896
  Psmd6                                       Proteasome 26S subunit, non-ATPase, 6                         2893                                     2460                      3000
  Psmd7                                       Proteasome 26S subunit, non-ATPase, 7                         2678                                     2492                      2579
  Psmd8                                       Proteasome 26S subunit, non-ATPase, 8                         2601                                     2684                      2594
  Psmd9                                       Proteasome 26S subunit, non-ATPase, 9                         1228                                     916                       1206
  Psme1                                       Proteasome activator subunit 1 (PA28 alpha)                   4330                                     4983                      2175
  Psme2                                       Proteasome activator subunit 2 (PA28 beta)                    769                                      903                       391
  Psme3                                       Proteasome activator subunit 3 (PA28 gamma, Ki)               2495                                     2173                      1951
  Psme4                                       Proteasome activator subunit 4                                2923                                     2697                      2175
  Psmf1                                       Proteasome inhibitor subunit 1                                950                                      918                       926
  Psmg1                                       Proteasome assembly chaperone 1                               442                                      414                       384
  Psmg2                                       Proteasome assembly chaperone 2                               1435                                     1081                      1677
  Psmg3                                       Proteasome assembly chaperone 3                               283                                      232                       243
  Psmg4                                       Proteasome assembly chaperone 4                               667                                      591                       494
  **OTHER PEPTIDASES FOR MHC-I PROCESSING**                                                                                                                                    
  Tpp1                                        Tripeptidyl peptidase I                                       11374                                    9235                      6824
  Tpp2                                        Tripeptidyl peptidase II                                      2910                                     3005                      2429
  Nrd1                                        Nardilysin                                                    2694                                     2582                      3040
  Thop1                                       Thimet oligopeptidase 1                                       62                                       66                        82
  **TAP, TAPASIN, AND ERAP1**                                                                                                                                                  
  Tapbp                                       TAP binding protein                                           24961                                    29085                     11373
  Tap1                                        Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)   3796                                     3489                      565
  Tap2                                        Transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)   2398                                     2223                      630
  Erap1                                       Endoplasmic reticulum aminopeptidase 1                        1421                                     1467                      655
  Tapbpl                                      TAP binding protein-like                                      502                                      589                       222
  **CATHEPSINS**                                                                                                                                                               
  Ctsd                                        Cathepsin D                                                   32104                                    8139                      14906
  Ctsb                                        Cathepsin B                                                   15143                                    10660                     39555
  Ctsl                                        Cathepsin L                                                   13726                                    7431                      2687
  Ctsh                                        Cathepsin H                                                   3836                                     1095                      1823
  Ctss                                        Cathepsin S                                                   3670                                     1013                      46
  Ctsz                                        Cathepsin Z                                                   3352                                     3482                      2129
  Ctso                                        Cathepsin O                                                   3005                                     3189                      2627
  Ctsa                                        Cathepsin A                                                   2141                                     2659                      1973
  Ctsf                                        Cathepsin F                                                   709                                      351                       790
  Ctsk                                        Cathepsin K                                                   299                                      60                        123
  Ctsc                                        Cathepsin C                                                   89                                       338                       24
  Ctsg                                        Cathepsin G                                                   46                                       147                       2
  Ctsw                                        Cathepsin W                                                   19                                       53                        11
  Ctse                                        Cathepsin E                                                   2                                        7                         0
  **CYSTATINS**                                                                                                                                                                
  Cst3                                        Cystatin C                                                    13094                                    28792                     25352
  Cstb                                        Cystatin B                                                    9445                                     3702                      3390
  Cst10                                       Cystatin 10 (chondrocytes)                                    6582                                     16279                     22
  Cst6                                        Cystatin E/M                                                  67                                       66                        90
  Cstad                                       CSA-conditional, T cell activation-dependent protein          34                                       74                        12
  Csta                                        Cystatin A                                                    11                                       7                         5
  Cst7                                        Cystatin F (leukocystatin)                                    5                                        19                        2
  Cst9                                        Cystatin 9                                                    0                                        0                         7

*Data are reported as normalized gene expression levels as Fragments Per Kilobase of transcript per Million mapped reads (FPKM). Data is from Berendam. ([@B14])*.

Other non-proteasomal proteases have been implicated in MHC-I presentation ([@B15]). These additional peptidases can trim the proteasome-generated N-extended precursors or even destroy epitopes, by trimming below the size needed for presentation. Among these, LEC from both LN and lymphatic vessels express significant and comparable transcript levels of tripeptidyl peptidases I and II and nardilysin, but negligible levels of thimet \[[Table 1](#T1){ref-type="table"} and ([@B14])\]. The functional implications of these additional LEC proteases, in generating the LEC MHC immunopeptidome, are currently unknown.

Endosomes and Lysosomes
-----------------------

Late endosomes (LE) and lysosomes (Lyso) are sub-cellular compartments, present in all cell types, specialized for the degradation of endogenous and exogenous materials for maintenance of cellular proteostasis and, in immune cells, for immunosurveillance ([@B16]). These organelles characteristically exhibit a low acidic pH, high concentrations of proteases, and expression of lysosome-associated membrane protein (Lamp) protein family members ([@B16]). In professional antigen presenting cells, LE and Lyso are also enriched in MHC class II proteins and molecules that regulate peptide loading (Invariant Chain, DM and DO) ([@B17]--[@B21]) and are referred as MHC class II compartments (MIIC) ([@B22]). Ultrastructurally these compartments can appear with different morphologies: multivesicular, multilamellar, or a combination of both ([@B16]).

Multivesicular bodies (MVB) are late endosomal compartments with a diameter of between 400 and 500 nm and a limiting membrane that encloses several internal vesicles with diameters of between 40 and 90 nm ([@B16]). MVB receive bio-synthetic cargo from the trans-Golgi, cytosolic cargo through autophagy, and exogenous proteins through phagocytosis. MVB are ubiquitously distributed and ultrastructural analysis has shown their presence in LEC (LS, unpublished observation) ([@B23]). However, it is currently unknown whether all/or a fraction of these compartments are MHC-II positive and whether there are differences in MHC-II expression in MVBs under steady state and inflammatory conditions. On the other hand the multilamellar bodies (MLB), which are lysosomal-like compartment formed by concentric lamellae and particularly enriched in MHC class II molecules ([@B16]) are more specifically expressed in professional APCs, such as DCs, B cells and macrophages, and they have not been found in LEC (LS unpublished observation).

Invariant Chain, DM, and DO
---------------------------

The MHC II molecules in association with their chaperone Invariant Chain, traffic from the trans-Golgi network to the plasma membrane before internalization to the endosomal MIIC. Sorting signals on the cytosolic tail of the Invariant chain are recognized by the clathrin-coated vesicle machinery for transport to LE/Lyso, where the Invariant chain will be processed by Cathepsins to generate class II-associated invariant chain peptides (CLIP), which occupy the MHC II binding groove and will be exchanged with peptides derived from endosomal processing ([@B24]). MHC II/Invariant Chain complexes are present at high levels in LEC and confocal microscopy, performed on primary LEC indicates that MHC II is correctly targeted both at the cell surface and in endosomal compartments ([@B1]).

HLA-DM (H-2M in mice) is part of the endosomal antigen processing and presentation machinery and aids peptide loading onto MHC II molecules. HLA-DM (DM) was originally discovered following the analysis of B-cell lines that were inefficient at presenting peptides derived from the processing of phagocytosed proteins but easily presented peptides supplied exogenously ([@B17]--[@B19], [@B25], [@B26]). It was later determined that these cells were defective in the expression of either the HLA-DMA or HLA-DMB genes. Subsequent *in vitro* and *in vivo* experiments determined that the role of DM is to catalyze CLIP removal, stabilize empty MHC II molecules for peptide loading and skew the immunopeptidome repertoire toward high affinity peptides ([@B17], [@B25], [@B26]). Mice lacking H-2M expressed similar I-A^b^ MHC II cell surface levels as wild type mice. However, the I-A^b^ MHC II molecules were less compact/SDS-resistant and were predominantly associated with CLIP ([@B27]). In contrast, lack of DM led to decreased peptide capture by I-A^d^ molecules, but enhanced peptide loading by I-E^d^ MHC II molecules ([@B28]). Finally, lack of DM generated a substantial pool of empty or loosely occupied I-A^k^ MHC II conformers with increase peptide binding activity. Mass spectrometry profiles confirmed the presence of an MHC II-peptidome in absence of DM ([@B28], [@B29]). Additionally DM requirements are different for CLIP binding in different registers ([@B30]). These results demonstrate that DM has distinct roles depending on its specific class II partners.

Subsequently, an additional protein, DO, was discovered, whose role is to inhibit DM function ([@B18], [@B31]). Importantly, while DM expression is not greatly increased following pro-inflammatory stimuli (TLR activation) that induces dendritic cell maturation, DO is down-regulated ([@B32]). As such it was hypothesized that high DO expression in immature dendritic cells would inhibit DM activity and skew the MHC II peptidome toward a broader and less stably bound repertoire. Upon DC maturation, reduced DO expression would lead to high DM activity, shaping the peptide repertoire toward long-lived surface class II MHC complexes, thus promoting productive immune responses ([@B18], [@B33], [@B34]).

Transcript analysis has shown that Invariant chain, I-A alpha, and I-A beta are expressed significantly in LEC and BEC from LN, but not LEC from lymphatic vessels, but DM and DO expression is very low to negligible, albeit DM is up-regulated following inflammatory stimuli ([@B1], [@B4]) \[[Table 1](#T1){ref-type="table"} and ([@B14])\]. Because removal of CLIP from I-A^b^ molecules is strongly DM dependent, this could explain the inefficient processing and presentation of I-A^b^ restricted antigens by LEC ([@B1]). However, the haplotype variation data described above indicate that general conclusions about the ability of LEC to present MHC II restricted antigens should await analysis of other mouse haplotypes.

Cathepsins
----------

Cathepsins are a large family of serine, cysteine or aspartyl proteases that are present in endo-lysosomal compartments, and may be secreted at steady state or during pathological conditions ([@B35]). Cathepsins are most active at acid pH, can still function at neutral pH but are inactive at alkaline pH ([@B36]). Although these enzymes are present in most cells, certain cathepsins are enriched in particular antigen presenting cells. For example, Cathepsin S is highly expressed in dendritic cells and B cells, Cathepsin F in macrophages, and Cathepsin L in thymocytes ([@B36]--[@B41]).

Transcriptome analysis indicated that LEC from vessels express relatively low levels of cathepsins L and F, and negligible levels of Cathepsin S, while the levels of Cathepsin S and L were significantly elevated in LEC from LN \[[Table 1](#T1){ref-type="table"} and ([@B14])\]. However, measured Cathepsin L activity was variable among LN LEC and not evident in LEC from diaphragm ([@B1]). The activity of Cathepsin L indicates that at least some LEC could potentially cleave the Invariant Chain and generate CLIP peptides ([@B1]). Additionally, LEC could not efficiently process HA (an influenza membrane protein) and the IE-α protein as determined by either CD4 T cell recognition of the MHC II presented HA epitope or FACS analysis using the Y-Ae Ab that recognize I-Ab molecules loaded with the IE-α epitope, either under basal conditions or upon IFNγ stimulation ([@B1]). Furthermore, new evidence indicates that LEC express high levels of Cystatin C, B and 10 \[[Table 1](#T1){ref-type="table"} and ([@B14])\], which function as natural inhibitors of cathepsins ([@B42]). Altogether, the data point to the possibility that CatL and S activity in LEC is diminished, which could affect the generation of LIP10 and CLIP, and might also diminish the processing of other endogenous antigens.

Exogenous Peptides Binding and Antigen Exchange
-----------------------------------------------

The MHC I and MHC II presented immunopeptidome not only derives from endosomally processed proteins but also from pre-processed peptides that can be directly acquired from the extracellular milieu. Recent proteomic analyses have indicated that processed peptides are present in every biological fluid, among which lymph and blood, have been best characterized ([@B43]--[@B50]). The Eisen and Raghavan groups demonstrated binding of extracellular peptides to MHC I molecules and their regulation of CD8 T cell function ([@B51], [@B52]). Our group, among others, characterized extracellular peptide binding to MHC II surface molecules ([@B44], [@B53]--[@B57]). We determined that peptides carried in lymph were present in the HLA-DR1 immunopeptidome of immature dendritic cells and some of these peptides were not generated by endosomal processing, pinpointing the physiological relevance of MHC II surface/early endosomes loading ([@B44]). As such, the peptides present in the lymph, which derive from the metabolic and catabolic process of different parenchymal organs could contribute to the LEC MHC II immunopeptidome, since it has already been shown that LEC can readily bind and present pre-processed peptides ([@B1]).

Phagocytosis and Autophagy {#s2}
==========================

Only very recently LEC have been analyzed for their ability to capture exogenous and endogenous antigens through phagocytosis. *In vivo* experiments using fluorescently labeled OVA indicated that within 90 min the subcutaneously injected protein was identified in LYVE-1^+^ cells, present in LN sub-capsular sinuses ([@B7]). Additionally, genes encoding several scavenger receptors, known to be involved in receptor-mediated endocytosis, are upregulated in LEC from lymph node ([@B14]). LEC efficiency in processing phagocytosed proteins through the MHC II pathway in steady state condition is low ([@B1]); nevertheless LEC can transfer Ags to dendritic cells, which are known to be present in close proximity with LEC in the lymphatic capillary and collectors, to induce CD4 T-cell anergy ([@B1], [@B58]). In addition, LEC efficiently present MHC-I peptides, and it has been reported that phagocytosis in early endosomes can route exogenous antigens (both self and non self) for cross-presentation on MHC class I in a proteasome and TAP-1-dependent manner ([@B1], [@B3], [@B7], [@B58]--[@B61]). It is interesting to consider that the acquisition of cross-presented material is mediated by these scavenger receptors. A second mechanism that can transfer endogenous proteins in the endosomes is autophagy. Although autophagy has been extensively characterized in BEC ([@B62]), there are no reports on the role of autophagy in antigen processing and presentation in LEC.

LEC and Pathogen Immunity {#s3}
=========================

A growing body of evidences indicates that LEC are involved in immune response to pathogens. It has been recently reported that in extrapulmonary tuberculosis, the lymphatic system is the most common site of infection and LEC function as a niche for *Mycobacterium tuberculosis* ([@B59]). Indeed *M. tuberculosis* can replicate in the LEC cytosol and within autophagosomes suggesting that LEC are a previously unrecognized site for infection persistence. Similarly, Hantaviruses have been shown to have a tropism for lymphatic vessels and LEC infection with either Andes virus and Hantaan virus induces LEC hyperpermeabilization and pulmonary edema ([@B63]). The edema can be inhibited by α~v~β~3~ integrin as well as VEGFR3 antibodies ([@B63]). A LEC role in HIV infection was also reported in promoting infection and latency formation in resting CD4+ T cells ([@B64], [@B65]). Recently an interesting role of LEC in antigen persistence, after resolution of the infection, has been shown ([@B66]). After viral challenge and vaccination, the antigen was captured by LEC under proliferative conditions and stored for extended periods of time. This "antigen archiving" mechanism positively influenced the degree of protective immunity provided by circulating memory CD8^+^ T-cells ([@B66], [@B67]).

Costimulatory and Co-Inhibitory Molecules {#s4}
=========================================

Effective activation of T-cells requires the display of MHC-I and MHC-II-peptide complexes as well as an antigen-independent signals provided by co-stimulatory molecules, among which CD40, CD80 (B7.1), and CD86 (B7.2) have been extensively analyzed in their requirements for naïve and memory T-cells activation ([@B68], [@B69]). LN LEC were shown to express very low levels of CD40 and negligible levels of CD80 and CD86 ([@B3], [@B60]). More recent transcriptome analysis has validated these observations, and extended them to include additional costimulatory molecules \[[Table 1](#T1){ref-type="table"} and ([@B14])\]. Importantly these costimulatory molecules did not up-regulate following stimulation with an MHC-I cognate ligand as well as inflammatory signals (TLRs binders or IFNγ) ([@B3], [@B60]).

In contrast, LEC in LN, but not in peripheral tissue lymphatics, express multiple inhibitory receptors that engage counter-receptors on activated T-cells to dampen the immune response ([@B69]). These include PD-L1 (CD274) and PD-L2 (CD273), which are present on resting LEC and greatly up-regulated by inflammatory stimuli ([@B1], [@B70]). Interestingly, the ligand for LAG-3, another inhibitory receptor on T-cells, is MHC-II, and induction of CD8 T-cell tolerance by LEC depends on engagement of LAG-3 as well as PD-1 ([@B1], [@B60]). Consequently, it has been suggested that in the absence of functional Ag presentation, the expression of MHC-II molecules on LEC is concerned with inducing Lag-3 mediated tolerance. While the low expression of costimulatory molecules would suggest that LEC would be unable to activate T-cells, they stimulate profound proliferation of CD8 T-cells *in vivo* and *in vitro*, and after peptide pulsing and CD4 T-cell proliferation *in vitro* ([@B58], [@B60]). However, the expression of the co-inhibitory molecules leads to deletional tolerance of CD8 T-cells due to a failure to sustain upregulation of the IL-2 receptor. Thus, LEC represent an important mechanism for mediation of systemic peripheral tolerance ([@B58], [@B60], [@B61]).

Exosomes and Other Vesicles {#s5}
===========================

Most cells in the human body release vesicles of different sizes and content which can be classified as apoptotic bodies, micro and macrovesicles and exosomes ([@B71]). Exosomes are small (30--120 mm) vesicles generated from the multivesicular late endosomes upon fusion with the plasma membrane and release in the extracellular milieu. Exosomes from different sources have been shown to transport a protein cargo as well as mRNAs and microRNAs. Their physiological and pathological relevance has been established in several immune and cancer-related models ([@B72]). Although very little is known about LEC-released exosomes, recently it has been shown that LEC release a vesicular fraction, which includes exosomes, following an inflammatory signal ([@B73]). The LEC-derived exosomes are reportedly enriched with a motility-promoting protein signature, which act as a cue for the dendritic cells migratory response ([@B73]). In particular LEC released vesicles accumulate in the perivascular stroma of small lymphatic vessels, mostly in the presence of inflammatory cytokines and promote directional migration of CX3CR1-expressing cells ([@B73]).

Concluding Remarks {#s6}
==================

LEC cells are anatomically placed between parenchymal organs and draining lymph nodes, functioning as a conduit for the lymphatic fluid and are known to control DC and T cell migration in and out of the lymph node ([@B74], [@B75]). During the last few years their functionality in antigen processing and presentation and T cell immune responses has emerged. Under steady-state conditions LEC can present self-antigens to induce T cell tolerance either through expression of peripheral tissue antigens ([@B76]) or acquisition of extracellular antigens through phagocytosis or by acquisition of pre-loaded MHC II molecules from DC. Under inflammatory conditions LEC also play an immunosuppressive role by decreasing DC maturation ([@B77]) and by up-regulating surface PDL1 ([@B76]).

However, the advances in understanding the cross-talk between LEC and T cells has not been paralleled by a detailed mechanistic analysis of their antigen processing and presentation machinery. Characterization of LEC immunoproteasomes, endosomal processing compartments, and antigen acquisition from the lymphatic fluid still needs to be investigated. Nevertheless, the work to date points to an emerging picture of the role played by LEC in maintenance of self-tolerance.
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BEC

:   blood endothelial cells

LEC

:   lymphatic endothelial cells

LN

:   lymph node

LN-BEC

:   lymph node-associated blood endothelial cells

LN-LEC

:   lymph node-associated lymphatic endothelial cells

DC

:   dendritic cells

LE

:   late endosomes

Lyso

:   lysosomes

MIIC

:   MHC class II compartments

MVB

:   multivesicular bodies

MLB

:   multilamellar bodies

DM

:   HLA-DM

Ii

:   invariant chain

DO

:   HLA-DO.
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